DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc 1 .

MLA

Braillard, Stéphanie, et al. “DNDI-6174 Is a Preclinical Candidate for Visceral Leishmaniasis That Targets the Cytochrome Bc 1 .” Science Translational Medicine, vol. 15, no. 726, Dec. 2023, p. eadh9902. EBSCOhost, https://doi.org/10.1126/scitranslmed.adh9902.

APA

Braillard, S., Keenan, M., Breese, K. J., Heppell, J., Abbott, M., Islam, R., Shackleford, D. M., Katneni, K., Crighton, E., Chen, G., Patil, R., Lee, G., White, K. L., Carvalho, S., Wall, R. J., Chemi, G., Zuccotto, F., González, S., Marco, M., … Chatelain, E. (2023). DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc 1 . Science Translational Medicine, 15(726), eadh9902. https://doi.org/10.1126/scitranslmed.adh9902

Chicago

Braillard, Stéphanie, Martine Keenan, Karen J Breese, Jacob Heppell, Michael Abbott, Rafiqul Islam, David M Shackleford, et al. 2023. “DNDI-6174 Is a Preclinical Candidate for Visceral Leishmaniasis That Targets the Cytochrome Bc 1 .” Science Translational Medicine 15 (726): eadh9902. doi:10.1126/scitranslmed.adh9902.